Bangalore, Oct 14,2008: Wanbury, has launched its Drug Delivery System (NDDS) product, Nitrofur SR, which is targeted at Urinary Tract Infections (UTI).

 

"Wanbury's Nitrofur SR, due to its unique hydrophilic polymer matrix or HPM technology, makes it a once-a-day, sustained release product. It is highly-effective compared to instant release formulations and is without any side-effects," said Rajaram Samant, Director (Marketing and Sales), Wanbury.

 

According to industry estimates, the size of the UTI market in India is about $250 million (Rs 1,200 crore), and growing annually at 14  percent. It is alarming that in  India over 28 percent of women visiting gynecologists suffer from UTI.

 

"We will be targeting this 28 percent population. We plan Nitrofur SR sales of Rs 100 million in the first year of the launch and hope to capture a substantial share of the UTI market in the next three years," he said.